TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16052765

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop/Z100 (3M ESPE)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tyrian One-Step Plus/AeliteFil (Bisco)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus SE/Prodigy (SDS Kerr)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Xeno III/TPH (Dentsply Caulk)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control: Prime&Bond NT/TPH (Dentsply Caulk)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control: Z100
Number of subjects: 200
Study: 12193491

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 50 micro g and morphine 500 micro g
Number of subjects: 24
Study: 10063812

Group type: EXPERIMENTAL
Intervention: Creatine (C: 25 g X d(‐1) for 5 d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study: 7734252

Group type: COMPARATOR
Intervention: Ephedrine alone (0.2 mg kg‐1 bolus followed by 0.5 mg kg‐1 h‐1 infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ephedrine and colloid (polygeline, Haemaccel) 8 ml kg‐1
Number of subjects: 30
Study: 1791077

Group type: EXPERIMENTAL
Intervention: Monotherapy with cefotaxime
Number of subjects: 588
Study: 7059416

Group type: EXPERIMENTAL
Intervention: Prorenoate potassium
Number of subjects: 12

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both compounds
Number of subjects: 12
Study: 31245333

Group type: EXPERIMENTAL
Intervention: Syringe with attached angiocath tubing
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Elephant Ear Washer Bottle System®
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: OtoClear® Spray Wash Kit
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Metal curette
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall procedures
Number of subjects: 38
Study: 28119083

Group type: EXPERIMENTAL
Intervention: Modafinil (2×200mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Methylphenidate (2×20mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Caffeine (2×200mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 27029801

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Hall Technique (HT)
Number of subjects: 124
Study: 25007392

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 2044

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 2044

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2044

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg
Number of subjects: 2044

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 2044
Study: 22219027

Group type: EXPERIMENTAL
Intervention: Prolonged exposure to a single direction of motion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychophysically measured adaptation tuning curves
Number of subjects: 0
Study: 19291114

Group type: EXPERIMENTAL
Intervention: Maggot debridement therapy (MDT) with Lucilia cuprina
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional debridement
Number of subjects: 29
Study: 16784318

Group type: EXPERIMENTAL
Intervention: Covered self-expanding stent
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bare self-expanding stent
Number of subjects: 14
Study: 14735048

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (Duraflo II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-coated circuit (control)
Number of subjects: 30
Study: 10889289

Group type: EXPERIMENTAL
Intervention: HF‐rTMS of the LPFC (real stimulation)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham stimulation of the LPFC
Number of subjects: 25
Study: 8865378

Group type: EXPERIMENTAL
Intervention: TENS applied over the second intercostal spaces during inspiration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: TENS applied over the second intercostal spaces during expiration
Number of subjects: 11

Group type: COMPARATOR
Intervention: TENS applied over the deltoid muscles during inspiration (control)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No TENS applied (fourth occasion)
Number of subjects: 11
Study: 1633839

Group type: COMPARATOR
Intervention: Conventional injection of glucagon (1 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucagon injection with CGRP (10 nmole)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucagon injection using a multihole 'sprinkler' needle
Number of subjects: 6
Study: 6405428

Group type: EXPERIMENTAL
Intervention: Intravenous d-amphetamine sulphate (15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral d-amphetamine sulphate (15 mg)
Number of subjects: 0
Study: 31492766

Group type: EXPERIMENTAL
Intervention: 1 ppm of EGF ointment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 20 ppm of EGF ointment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EGF arms (1 ppm and 20 ppm)
Number of subjects: 80
Study: 31175209

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) with 10 Hz stimulation for 10 sessions.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS (control group).
Number of subjects: 30
Study: 28079557

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (20 μg kg‐1 min‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no dobutamine)
Number of subjects: 24
Study: 25500486

Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor tablets administered orally
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor tablets administered via nasogastric tube
Number of subjects: 36

Group type: COMPARATOR
Intervention: Whole ticagrelor tablets administered orally
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor tablets (both methods)
Number of subjects: 36
Study: 23421629

Group type: COMPARATOR
Intervention: Gluma Desensitizer (Heraeus Kulzer)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nd:YAG Laser (Power Laser™ ST6, Lares Research®)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nd:YAG Laser + Gluma Desensitizer
Number of subjects: 30
Study: 21551475

Group type: EXPERIMENTAL
Intervention: DDDR (rate responsive pacing)
Number of subjects: 13

Group type: COMPARATOR
Intervention: DDD (control)
Number of subjects: 13
Study: 19660002

Group type: EXPERIMENTAL
Intervention: Udenafil 200 mg oral dose under fasting conditions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Udenafil 200 mg oral dose after a low-fat meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Udenafil 200 mg oral dose after a high-fat meal
Number of subjects: 15
Study: 16537872

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard chest physiotherapy (SCPT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HFCWO
Number of subjects: 10

Group type: COMPARATOR
Intervention: SCPT
Number of subjects: 10
Study: 15462701

Group type: EXPERIMENTAL
Intervention: Symbicort adjustable maintenance dosing plan (SAMD) - budesonide/formoterol 1-4 inhalations twice daily depending on symptoms
Number of subjects: 1553

Group type: COMPARATOR
Intervention: Symbicort fixed dosing - 2 inhalations twice daily
Number of subjects: 1553

Group type: EXPERIMENTAL
Intervention: SAMD
Number of subjects: 1553

Group type: COMPARATOR
Intervention: Fixed dosing
Number of subjects: 1553
Study: 11477028

Group type: EXPERIMENTAL
Intervention: Powerlifters
Number of subjects: 45

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 45
Study: 9757853

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (13 mg/m2 every morning and 3 mg/m2 every afternoon for approximately 12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 70
Study: 7818065

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with intravenous pethidine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nurse-controlled pethidine infusions
Number of subjects: 200
Study: 2967622

Group type: EXPERIMENTAL
Intervention: 0.9 mg Zoladex
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.8 mg Zoladex
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3.6 mg Zoladex
Number of subjects: 90
Study: 29544738

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (100 mg for ages 2-11, 200 mg for ages 12-17)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 26111163

Group type: EXPERIMENTAL
Intervention: Letter condition
Number of subjects: 115

Group type: COMPARATOR
Intervention: No-letter condition
Number of subjects: 115
Study: 26354560

Group type: EXPERIMENTAL
Intervention: Blood Volume Monitoring (BVM) treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no BVM treatment)
Number of subjects: 14
Study: 22527264

Group type: EXPERIMENTAL
Intervention: Human rights‐based intervention approach with four dialogical meetings focused on medication intake scenes
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 121
Study: 20184444

Group type: EXPERIMENTAL
Intervention: 1 g of paracetamol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 8 mg of lornoxicam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of tramadol
Number of subjects: 90
Study: 19032138

Group type: EXPERIMENTAL
Intervention: SFC (salmeterol/fluticasone propionate) 50/250 microg bd or 50/500 microg bd via Diskus
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: SFC (salmeterol/fluticasone propionate)
Number of subjects: 424

Group type: COMPARATOR
Intervention: CC (current care)
Number of subjects: 424
Study: 17157780

Group type: EXPERIMENTAL
Intervention: Oxytrex (oxycodone + ultralow-dose naltrexone) bid
Number of subjects: 719

Group type: COMPARATOR
Intervention: Oxycodone qid
Number of subjects: 719
Study: 12728375

Group type: EXPERIMENTAL
Intervention: Monofile, heavy-weight, rigid mesh (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Smooth, heavy-weight variant of polypropylene mesh (group B)
Number of subjects: 40
Study: 10681282

Group type: EXPERIMENTAL
Intervention: Potato chips containing 40 g of olestra per day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional potato chips (control)
Number of subjects: 10
Study: 9148019

Group type: EXPERIMENTAL
Intervention: HLA-DR expression on bile ducts in advanced primary biliary cirrhosis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: B7-2 expression on bile ducts in advanced primary biliary cirrhosis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: B7-1 expression on bile ducts in advanced primary biliary cirrhosis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: B7-1 and B7-2 expression on bile ducts in early primary biliary cirrhosis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: HLA-DR, B7-1, and B7-2 expression on professional antigen presenting cells
Number of subjects: 31

Group type: COMPARATOR
Intervention: Co-expression of B7-1 and B7-2 on HLA-DR+ bile ducts in autoimmune hepatitis
Number of subjects: 31
Study: 8436635

Group type: EXPERIMENTAL
Intervention: F2 (2500 alternations per minute)
Number of subjects: 0

Group type: COMPARATOR
Intervention: F1 (2100 alternations per minute)
Number of subjects: 0

Group type: COMPARATOR
Intervention: F3 (3500 alternations per minute)
Number of subjects: 0
Study: 3301923

Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream once daily
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream twice daily
Number of subjects: 62
Study: 29534134

Group type: COMPARATOR
Intervention: Tissue-level implants restored with platform matching (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bone-level implants restored with platform switching (test group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Comparison between both groups
Number of subjects: 100
Study: 26334577

Group type: EXPERIMENTAL
Intervention: Idiopathic PVT (IPVT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: SPVT
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (C-IPVT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: IPVT
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Waist circumference increase
Number of subjects: 79
Study: 25201794

Group type: EXPERIMENTAL
Intervention: SSI reduction bundle (prohibition of razors, chlorhexidine-alcohol use, correct timing of prophylactic antibiotics)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Correct timing of preoperative prophylactic antibiotics
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Achievement of 0 SSIs per center
Number of subjects: 8
Study: 24712192

Group type: EXPERIMENTAL
Intervention: Volar plate
Number of subjects: 69

Group type: COMPARATOR
Intervention: External fixator
Number of subjects: 69
Study: 19349870

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir monotherapy
Number of subjects: 198

Group type: COMPARATOR
Intervention: Triple therapy (lopinavir-ritonavir and 2 nucleosides)
Number of subjects: 198
Study: 17224426

Group type: EXPERIMENTAL
Intervention: Novel catheter for simultaneous angiography of ipsilateral pulmonary veins
Number of subjects: 0
Study: 16025024

Group type: EXPERIMENTAL
Intervention: CHARITE artificial disc
Number of subjects: 304

Group type: COMPARATOR
Intervention: Anterior lumbar interbody fusion
Number of subjects: 304
Study: 12399672

Group type: EXPERIMENTAL
Intervention: Sequential therapy (potent topical steroids + 20% azelaic acid cream)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 20% azelaic acid cream monotherapy
Number of subjects: 30
Study: 18653145

Group type: EXPERIMENTAL
Intervention: Caloric restriction
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Controlled physical exercise
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combination of caloric restriction and physical exercise with pharmacological treatment
Number of subjects: 74
Study: 7660761

Group type: EXPERIMENTAL
Intervention: 2‐h blood glucose value of 8.0 to 8.9 mmol/l
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (2‐h blood glucose value < 8.0 mmol/l)
Number of subjects: 223
Study: 2178992

Group type: EXPERIMENTAL
Intervention: Femodene
Number of subjects: 456

Group type: COMPARATOR
Intervention: Microgynon-30
Number of subjects: 456
Study: 327948

Group type: EXPERIMENTAL
Intervention: Erbium 169 injection (+prednisolone acetate)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline injection (+prednisolone acetate)
Number of subjects: 36
Study: 31081712

Group type: EXPERIMENTAL
Intervention: Er;Cr:YSGG laser treatment at 3.75 W power and 15 Hz frequency for 4 min
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hydrofluoric (HF) acid treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: L1S treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: L2D treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: L1D treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: L2S treatment
Number of subjects: 110
Study: 25985392

Group type: EXPERIMENTAL
Intervention: Incredible Years parenting intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 154
Study: 26407357

Group type: EXPERIMENTAL
Intervention: Personal protective equipment (PPE) use when caring for patients with suspected pertussis
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Personal protective equipment (PPE) use for patients with any respiratory symptoms
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Attitudes toward PPE
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Knowledge and skills regarding PPE
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Perceived barriers to PPE use
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Perception of PPE use as a norm
Number of subjects: 343

Group type: COMPARATOR
Intervention: Perceived infection risk or mask accessibility
Number of subjects: 343
Study: 23234638

Group type: EXPERIMENTAL
Intervention: Myofascial physical therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Global therapeutic massage
Number of subjects: 48
Study: 21690592

Group type: EXPERIMENTAL
Intervention: Home BP measurements using a monitor that transmitted measurements electronically
Number of subjects: 444

Group type: COMPARATOR
Intervention: Clinic BP measurements obtained during outpatient visits
Number of subjects: 444

Group type: COMPARATOR
Intervention: Standardized research BP measurements at 6‐month intervals
Number of subjects: 444
Study: 19506377

Group type: EXPERIMENTAL
Intervention: Unsafe injecting practices (receptive syringe sharing after an HIV‐infected IDU)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Unsafe injecting practices (distributive syringe sharing)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Unsafe injecting practices (sharing cookers)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Unsafe injecting practices (sharing filters)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Unsafe injecting practices (syringe‐mediated drug sharing)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Correlates of unsafe injecting (urban environmental characteristics)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Correlates of unsafe injecting (social norms)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Correlates of unsafe injecting (cleaning used syringes)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Correlates of unsafe injecting (self‐report of HIV infection)
Number of subjects: 446
Study: 16884321

Group type: EXPERIMENTAL
Intervention: FBT administered as four 100 microg tablets simultaneously
Number of subjects: 27

Group type: COMPARATOR
Intervention: FBT administered as one 400 microg tablet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Arterial sampling
Number of subjects: 27

Group type: COMPARATOR
Intervention: Venous sampling
Number of subjects: 27
Study: 16004743

Group type: EXPERIMENTAL
Intervention: Dissemination of full guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prioritised review criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Criteria plus feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (other interventions)
Number of subjects: 0
Study: 12858158

Group type: EXPERIMENTAL
Intervention: Imprint cytology
Number of subjects: 38

Group type: COMPARATOR
Intervention: Frozen-section biopsy (FSB)
Number of subjects: 38
Study: 9927370

Group type: EXPERIMENTAL
Intervention: 2 ppm of NO2 for 4 h on four consecutive days
Number of subjects: 0
Study: 7571476

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg or 8 mg administered once a day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of perindopril with hydrochlorothiazide
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Perindopril (monotherapy and combination)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 31
Study: 2153736

Group type: EXPERIMENTAL
Intervention: Topical 15% idoxuridine in dimethyl sulfoxide
Number of subjects: 301

Group type: COMPARATOR
Intervention: 80% DMSO control solution
Number of subjects: 301

Group type: COMPARATOR
Intervention: 2% DMSO control solution
Number of subjects: 301
Study: 6792978

Group type: EXPERIMENTAL
Intervention: Lactinex
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30326318

Group type: EXPERIMENTAL
Intervention: Biographical suspension concept
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Symptom resolution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Suspended liminality
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ongoing symptoms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: State of being between sickness and wellness
Number of subjects: 20
Study: 27974224

Group type: EXPERIMENTAL
Intervention: Videotaped (DVD) parenting skills intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 60
Study: 25727393

Group type: EXPERIMENTAL
Intervention: Smoke available in 24 hours
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Smoke available in 3 hours
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Smoke available in 20 minutes
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Self-reported urge
Number of subjects: 90
Study: 22831752

Group type: EXPERIMENTAL
Intervention: Monocortical locking plate (group A; n = 28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bicortical screw (group B; n = 27)
Number of subjects: 55
Study: 21036514

Group type: EXPERIMENTAL
Intervention: Inpatient setting
Number of subjects: 68

Group type: COMPARATOR
Intervention: Outpatient setting
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both settings
Number of subjects: 68
Study: 18319227

Group type: EXPERIMENTAL
Intervention: Levo-propionyl-carnitine (LPC) during supervised physical training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised physical training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPC infusions
Number of subjects: 0
Study: 17000941

Group type: EXPERIMENTAL
Intervention: Electronic medical record reminder
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Automated voice message
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Pharmacy team outreach
Number of subjects: 961

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 961
Study: 14520243

Group type: EXPERIMENTAL
Intervention: Nonclosure of peritoneum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closure of peritoneum
Number of subjects: 0
Study: 10743823

Group type: EXPERIMENTAL
Intervention: Tramadol (200-400 mg/day)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 380
Study: 8937605

Group type: EXPERIMENTAL
Intervention: DDAVP (20 micrograms infused over one-half hour)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no DDAVP)
Number of subjects: 20
Study: 1458526

Group type: EXPERIMENTAL
Intervention: Percutaneously applied collagen (group A; n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional pressure dressing (group B; n = 50)
Number of subjects: 100